The prognostic value of time from symptom onset to thrombolysis in patients with pulmonary embolism

Basit Öğe Kaydı
dc.authorscopusid56305045000
dc.authorscopusid57211592457
dc.authorscopusid57217415175
dc.authorscopusid23669358200
dc.authorscopusid55901468500
dc.authorscopusid55606161300
dc.authorscopusid57225681216
dc.contributor.authorKeskin, Muhammed
dc.contributor.authorDoğan, Selami
dc.contributor.authorKaya, Adnan
dc.contributor.authorTenekecioğlu, Erhan
dc.contributor.authorÖcal, Lütfi
dc.contributor.authorCerşit, Sinan
dc.contributor.authorŞeker, Mehmet
dc.date.accessioned2023-07-26T11:50:58Z
dc.date.available2023-07-26T11:50:58Z
dc.date.issued2022
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalıen_US
dc.description.abstractBackground: According to clinical practice guidelines, thrombolysis can be administered during the 14 days after the beginning of symptoms in PE. However, the role of the early thrombolysis in PE has not been comprehensively investigated. In this study we evaluated the effect of short symptom-to-thrombolysis time (STT) in these patients who received the thrombolytic therapy within the 48-h. Method: A total of 456 patients with pulmonary embolism who underwent thrombolytic therapy in a tertiary center were included in the current study. The patients were stratified into three groups according to STT as: <12 h (Group 1), 12 to 24 h (Group 2) and > 24 to 48 h (Group 3). In-hospital events and long-term mortality were compared between the groups. Results: Group 3 had higher in-hospital mortality, acute kidney injury, cardiogenic shock, asystole, and the use mechanical ventilation and 3-year mortality compared to the other two groups. The 3-year overall survival for Group 1, 2 and 3 were 82.1%, 77.7% and 25.9% respectively. According to regression analysis, a STT > 24 h was independently associated with in-hospital and long-term mortality. Group 1 and 2 had similar in-hospital outcomes and long-term mortality. Conclusion: A short STT has a great importance in patients with PE who treated with thrombolytic therapy. The efficacy of systemic thrombolysis significantly drops after 24 h. Because of this situation, the period between the symptom onset and thrombolytic therapy should be kept short as much as possible. © 2022en_US
dc.identifier.doi10.1016/j.ijcard.2022.01.006
dc.identifier.endpage136en_US
dc.identifier.issn0167-5273
dc.identifier.pmid35051492en_US
dc.identifier.scopus2-s2.0-85123236359en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage131en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijcard.2022.01.006
dc.identifier.urihttps://hdl.handle.net/20.500.12684/12468
dc.identifier.volume352en_US
dc.identifier.wosWOS:000793677500024en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKaya, Adnan
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofInternational Journal of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectPulmonary embolismen_US
dc.subjectThrombolysisen_US
dc.subjecttissue plasminogen activatoren_US
dc.subjectfibrinolytic agenten_US
dc.subjectacute kidney failureen_US
dc.subjectageden_US
dc.subjectall cause mortalityen_US
dc.subjectArticleen_US
dc.subjectartificial ventilationen_US
dc.subjectbleedingen_US
dc.subjectbrain hemorrhageen_US
dc.subjectcardiogenic shocken_US
dc.subjectcontrolled studyen_US
dc.subjectfemaleen_US
dc.subjectfibrinolytic therapyen_US
dc.subjectheart arresten_US
dc.subjecthumanen_US
dc.subjectin-hospital mortalityen_US
dc.subjectlong term mortalityen_US
dc.subjectlung embolismen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmortalityen_US
dc.subjectmortality rateen_US
dc.subjectoverall survivalen_US
dc.subjectprognosisen_US
dc.subjectproportional hazards modelen_US
dc.subjectretrospective studyen_US
dc.subjectsurvival rateen_US
dc.subjectsymptom to thrombolysis timeen_US
dc.subjecttertiary care centeren_US
dc.subjecttimeen_US
dc.subjectadverse eventen_US
dc.subjectlung embolismen_US
dc.subjectprognosisen_US
dc.subjecttreatment outcomeen_US
dc.subjectFibrinolytic Agentsen_US
dc.subjectHumansen_US
dc.subjectPrognosisen_US
dc.subjectPulmonary Embolismen_US
dc.subjectThrombolytic Therapyen_US
dc.subjectTreatment Outcomeen_US
dc.titleThe prognostic value of time from symptom onset to thrombolysis in patients with pulmonary embolismen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
12468.pdf
Boyut:
454.63 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu